EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Prasugrel Intermediate Metabolite Modulates Platelet Inhibition by Negatively Interfering With an Active Metabolite: An Ex Vivo, In Vitro, and In Silico Study

Pietro Minuz iD, Alejandro Giorgetti, Alessandra Meneguzzi iD, Francesco Taus iD, Rui P Ribeiro iD, Filippo Baldessari iD, Giuseppe Gargiulo iD, Felice Gragnano iD, Antonio Landi, Marco Castelli iD, Rossella Gottardo iD, Federica Bortolotti iD und 5 weitere

Arteriosclerosis, Thrombosis, and Vascular Biology · 2025-05 · 45 (5) · 792-804

DOI: 10.1161/atvbaha.124.321916 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2025-05. Verfasst von Pietro Minuz und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Section of Internal Medicine C (P.M., A.M., F. Taus, M. Castelli, C.F.), University of Verona, Italy. Hauptthemen laut MEDLINE: Blood Platelets, Platelet Aggregation, Platelet Aggregation Inhibitors, Prasugrel Hydrochloride. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Prasugrel is converted into prasugrel active metabolite (PAM; R-138727) through the cytochrome P450–mediated conversion of an intermediate metabolite (PIM; R-95913). It is unknown whether PIM exerts any biological function. The FABOLUS-FASTER trial (Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over Prasugrel: A Multicenter Randomized Open-Label Trial in Patients With ST-Elevation Myocardial Infarction Referred for Primary Percutaneous Intervention) showed that chewed prasugrel does not improve bioactivity, in spite of accelerated PAM kinetics. METHODS: PIM and PAM pharmacokinetics were assessed by mass spectrometry in blood samples collected from ST-segment–elevation myocardial infarction patients randomized to chewed (n=17) or integral (n=15) 60 mg prasugrel. The ex vivo and in vitro effects of PAM and PIM were assessed on ADP-induced platelet activation. The binding sites of PIM and PAM were investigated by molecular dynamics simulation. RESULTS: Chewed prasugrel was associated with higher PIM levels compared with integral prasugrel: PIM median area under the curve (25–75 p): 73 (41.5–92.0) versus 33 (0.0–50.0) ng·h/mL ( P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood PlateletsPlatelet AggregationPlatelet Aggregation InhibitorsPrasugrel HydrochloridePurinergic P2Y Receptor AntagonistsST Elevation Myocardial InfarctionAgedFemaleHumansMaleMiddle AgedAdministration, OralBinding SitesCell Adhesion MoleculesMicrofilament ProteinsMolecular Docking SimulationMolecular Dynamics SimulationPhosphoproteinsPhosphorylationPlatelet ActivationReceptors, Purinergic P2Y12Vasodilator-Stimulated PhosphoproteinPiperazinesP-Selectin

Stichwörter der Autor:innen

drug interactionsmyocardial infarctionpharmacokineticsplatelet aggregationprasugrel hydrochloride

Substanzen

Cell Adhesion MoleculesMicrofilament ProteinsPhosphoproteinsPlatelet Aggregation InhibitorsPrasugrel HydrochloridePurinergic P2Y Receptor AntagonistsReceptors, Purinergic P2Y12Vasodilator-Stimulated PhosphoproteinPiperazinesP-Selectin

Autor:innen und Institutionen

  • Department of Medicine, Section of Internal Medicine C (P.M., A.M., F. Taus, M. Castelli, C.F.), University of Verona, Italy.
  • Department of Biotechnology (A.G., R.P.R., F. Baldessari), University of Verona, Italy.
  • Department of Diagnostics and Public Health, Unit of Forensic Medicine (F. Taus, R.G., F. Bortolotti, F. Tagliaro), University of Verona, Italy.
  • Department of Advanced Biomedical Sciences, University Federico II of Naples, Italy (G.G.).
  • Department of Translational Medical Sciences, University of Campania Luigi Vanvitelli, Caserta, Italy (F.G.).
  • Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Lugano, Switzerland (A.L., M.V.).

ORCID-Profile: Pietro Minuz, Alessandra Meneguzzi, Francesco Taus, Rui P Ribeiro, Filippo Baldessari, Giuseppe Gargiulo, Felice Gragnano, Marco Castelli, Rossella Gottardo, Federica Bortolotti, Giuseppe Verlato, Cristiano Fava, Marco Cattaneo, Franco Tagliaro, Marco Valgimigli

Zitieren

APA

Minuz, P., Giorgetti, A., Meneguzzi, A., Taus, F., Ribeiro, R. P., Baldessari, F., Gargiulo, G., Gragnano, F., Landi, A., Castelli, M., Gottardo, R., Bortolotti, F., Verlato, G., Fava, C., Cattaneo, M., Tagliaro, F., & Valgimigli, M. (2025). Prasugrel Intermediate Metabolite Modulates Platelet Inhibition by Negatively Interfering With an Active Metabolite: An Ex Vivo, In Vitro, and In Silico Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 45(5), 792-804. https://doi.org/10.1161/atvbaha.124.321916

Vancouver

Minuz P, Giorgetti A, Meneguzzi A, Taus F, Ribeiro RP, Baldessari F, et al. Prasugrel Intermediate Metabolite Modulates Platelet Inhibition by Negatively Interfering With an Active Metabolite: An Ex Vivo, In Vitro, and In Silico Study. Arteriosclerosis, Thrombosis, and Vascular Biology. 2025;45(5):792-804. doi:10.1161/atvbaha.124.321916

BibTeX
@article{Minuz2025,
  author = {Minuz, Pietro and Giorgetti, Alejandro and Meneguzzi, Alessandra and Taus, Francesco and Ribeiro, Rui P and Baldessari, Filippo and Gargiulo, Giuseppe and Gragnano, Felice and Landi, Antonio and Castelli, Marco and Gottardo, Rossella and Bortolotti, Federica and Verlato, Giuseppe and Fava, Cristiano and Cattaneo, Marco and Tagliaro, Franco and Valgimigli, Marco},
  title = {Prasugrel Intermediate Metabolite Modulates Platelet Inhibition by Negatively Interfering With an Active Metabolite: An Ex Vivo, In Vitro, and In Silico Study},
  journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
  year = {2025},
  volume = {45},
  number = {5},
  pages = {792--804},
  doi = {10.1161/atvbaha.124.321916}
}
Kostenlos starten →